Literature DB >> 26916546

RNA sequencing validation of the Complexity INdex in SARComas prognostic signature.

Tom Lesluyes1, Gaëlle Pérot2, Marine Roxane Largeau3, Céline Brulard4, Pauline Lagarde4, Valérie Dapremont5, Carlo Lucchesi6, Agnès Neuville2, Philippe Terrier7, Dominique Vince-Ranchère8, Maria Mendez-Lago9, Marta Gut9, Ivo Gut9, Jean-Michel Coindre10, Frédéric Chibon11.   

Abstract

BACKGROUND: Prognosis of metastatic outcome in soft tissue sarcomas is an important clinical challenge since these tumours can be very aggressive (up to 50% of recurring events). A gene expression signature, Complexity INdex in SARComas (CINSARC), has been identified as a better prognostic factor compared to the current international grading system defined by the Fédération Nationale des Centres de Lutte Contre le Cancer. Since CINSARC has been established on frozen tumours analysed by microarrays, we were interested in evaluating its prognostic capacity using next generation sequencing (NGS) on formalin-fixed, paraffin-embedded (FFPE) blocks to better fit laboratory practices.
METHODS: Metastatic-free survivals (training/validation approach with independent datasets) and agreement values in classification groups were evaluated. Also, RNA degradation threshold has been established for FFPE blocks and differences in gene expression due to RNA degradation were measured.
RESULTS: CINSARC remains a strong prognostic factor for metastatic outcome in both microarray and RNA-seq technologies (P < 0.05), with similar risk-group classifications (77%). We defined quality threshold to process degraded RNA extracted from FFPE blocks and measured similar classifications with frozen tumours (88%).
CONCLUSION: These results demonstrate that CINSARC is a platform and material independent prognostic signature for metastatic outcome in various sarcomas. This result opens access to metastatic prognostication in sarcomas through NGS analysis on both frozen and FFPE tumours via the CINSARC signature.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; High-throughput RNA sequencing; Metastasis; Sarcoma; Transcriptome

Mesh:

Substances:

Year:  2016        PMID: 26916546     DOI: 10.1016/j.ejca.2015.12.027

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  35 in total

1.  Differential immune profiles distinguish the mutational subtypes of gastrointestinal stromal tumor.

Authors:  Gerardo A Vitiello; Timothy G Bowler; Mengyuan Liu; Benjamin D Medina; Jennifer Q Zhang; Nesteene J Param; Jennifer K Loo; Rachel L Goldfeder; Frederic Chibon; Ferdinand Rossi; Shan Zeng; Ronald P DeMatteo
Journal:  J Clin Invest       Date:  2019-02-14       Impact factor: 14.808

2.  Biallelic Dicer1 Loss Mediated by aP2-Cre Drives Angiosarcoma.

Authors:  Jason A Hanna; Catherine J Drummond; Matthew R Garcia; Jonathan C Go; David Finkelstein; Jerold E Rehg; Mark E Hatley
Journal:  Cancer Res       Date:  2017-09-15       Impact factor: 12.701

Review 3.  Understanding preanalytical variables and their effects on clinical biomarkers of oncology and immunotherapy.

Authors:  Lokesh Agrawal; Kelly B Engel; Sarah R Greytak; Helen M Moore
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

4.  MIXnorm: normalizing RNA-seq data from formalin-fixed paraffin-embedded samples.

Authors:  Shen Yin; Xinlei Wang; Gaoxiang Jia; Yang Xie
Journal:  Bioinformatics       Date:  2020-06-01       Impact factor: 6.937

Review 5.  The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.

Authors:  Roman Groisberg; Jason Roszik; Anthony Conley; Shreyaskumar R Patel; Vivek Subbiah
Journal:  Curr Oncol Rep       Date:  2017-10-13       Impact factor: 5.075

6.  Comparative Transcriptome Analysis Quantifies Immune Cell Transcript Levels, Metastatic Progression, and Survival in Osteosarcoma.

Authors:  David A Largaespada; Jaime F Modiano; Subbaya Subramanian; Milcah C Scott; Nuri A Temiz; Anne E Sarver; Rebecca S LaRue; Susan K Rathe; Jyotika Varshney; Natalie K Wolf; Branden S Moriarity; Timothy D O'Brien; Logan G Spector; Aaron L Sarver
Journal:  Cancer Res       Date:  2017-10-24       Impact factor: 12.701

7.  Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.

Authors:  Naser M Ali; Stefania Niada; Anna T Brini; Mark R Morris; Sathishkumar Kurusamy; Abdullah Alholle; David Huen; Cristina R Antonescu; Franck Tirode; Vaiyapuri Sumathi; Farida Latif
Journal:  J Pathol       Date:  2018-12-27       Impact factor: 7.996

8.  Oncogenic Gene-Expression Programs in Leiomyosarcoma and Characterization of Conventional, Inflammatory, and Uterogenic Subtypes.

Authors:  Matthew L Hemming; Changyu Fan; Chandrajit P Raut; George D Demetri; Scott A Armstrong; Ewa Sicinska; Suzanne George
Journal:  Mol Cancer Res       Date:  2020-06-09       Impact factor: 5.852

9.  Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome.

Authors:  Matthew L Hemming; Matthew A Lawlor; Rhamy Zeid; Tom Lesluyes; Jonathan A Fletcher; Chandrajit P Raut; Ewa T Sicinska; Frédéric Chibon; Scott A Armstrong; George D Demetri; James E Bradner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-04       Impact factor: 11.205

10.  Calpain-6 controls the fate of sarcoma stem cells by promoting autophagy and preventing senescence.

Authors:  Caroline Andrique; Laetitia Morardet; Laetitia K Linares; Madi Y Cissé; Candice Merle; Frédéric Chibon; Sylvain Provot; Eric Haÿ; Hang-Korng Ea; Martine Cohen-Solal; Dominique Modrowski
Journal:  JCI Insight       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.